A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...
Zacks.com on MSN8h
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in EuropeBiogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...
Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...
A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...
Without a patient having to wait to see a specialist, the robot can run approximately 3.9 million tests per year on a ...
Biotech Analyst Fadia, along with Dr. Justin Long, discuss the factors influencing adoption of Alzheimer’s disease treatments, including ...
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback